Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Immunocore Holdings plc before investing.

In this article, we go over a few key elements for understanding Immunocore Holdings plc’s stock price such as:

• Immunocore Holdings plc’s current stock price and volume
• Why Immunocore Holdings plc’s stock price changed recently
• Upgrades and downgrades for IMCR from analysts
• IMCR’s stock price momentum as measured by its relative strength

About Immunocore Holdings plc (IMCR)

Before we jump into Immunocore Holdings plc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Want to learn more about Immunocore Holdings plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Immunocore Holdings plc.

Immunocore Holdings plc’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Immunocore Holdings plc’s stock price was $33.810.

Immunocore Holdings plc is down 0.18% from its previous closing price of $33.870.

During the last market session, Immunocore Holdings plc’s stock traded between $32.830 and $34.140. Currently, there are approximately 50.75 million shares outstanding for Immunocore Holdings plc.

Immunocore Holdings plc’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Immunocore Holdings plc Stock Price History

Immunocore Holdings plc’s (IMCR) price is currently up 6.49% so far this month.

During the month of July, Immunocore Holdings plc’s stock price has reached a high of $36.260 and a low of $30.290.

Over the last year, Immunocore Holdings plc has hit prices as high as $40.715 and as low as $27.555. Year to date, Immunocore Holdings plc’s stock is down 2.59%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Immunocore Holdings plc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 0 analysts who downgraded Immunocore Holdings plc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Immunocore Holdings plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Immunocore Holdings plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Immunocore Holdings plc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Immunocore Holdings plc (IMCR) by visiting AAII Stock Evaluator.

Relative Price Strength of Immunocore Holdings plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Immunocore Holdings plc has a weighted four-quarter relative price strength of 1.34%, which translates to a Momentum Score of 57 and is considered to be Average.

Want to learn more about how Immunocore Holdings plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Immunocore Holdings plc Stock Price: Bottom Line

As of July 31, 2026, Immunocore Holdings plc’s stock price is $33.810, which is down 0.18% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Immunocore Holdings plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.